模拟药物与器官的相互作用和优化免疫疗法:一个定量系统药理学和ODRONEXTAMAB动力学
11Department of Pharmacology and Toxicology, Faculty of Pharmacy, AlFarahidi University, Iraq.
Georgian medical news
|October 10, 2025
概括
定量系统药理学 (QSP) 建模优化心脏和脏药物以及B细胞非霍奇金淋巴瘤 (B-NHL) 患者的odronextamab剂量. 这种方法可以提高药物的疗效,并通过了解药物机制来最大限度地减少炎症反应.
科学领域:
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
- 在瘤学瘤学.
背景情况:
- 心血管和脏疾病是全球重要的健康问题.
- B细胞非霍奇金淋巴瘤 (B-NHL) 提出了治疗挑战.
- 双特异性抗体Odronextamab具有前景,但受到剂量相关炎症反应的限制.
- 定量系统药理 (QSP) 建模可以提供机理性见解和优化剂量.
研究的目的:
- 通过计算建模心脏脏药物的机制,并优化其剂量.
- 为B-NHL患者确定最佳的odronextamab剂量方案,以提高疗效并最大限度地减少炎症反应.
主要方法:
- 使用二次数据开发了一个QSP框架,整合了生理学,药理动力学和药理动力学参数.
- 模拟药物对脏和心血管的影响,使用诸如血压和膜过率等变量.
- 根据介质素-6 (IL-6) 反应和与现实数据对比的验证模型预测,评估了odronextamab 剂量方案.
主要成果:
- 心脏病药物改善了血压和喷射率.
- 确定了隐藏的盐损失作为一种机制,与糖和水分泌一起,改善脏调节.
- 组C (可变剂量) 显示了最有利的IL-6降低的odronextamab,导致提议的精细分剂方案.
结论:
- 通过盐,糖和水调节,提供了对心脏脏药物效应的机制性见解.
- 提出了一种经过验证的,优化的odronextamab剂量策略,降低IL-6水平并提高B-NHL患者的安全性.
- 与现实数据集成的QSP支持个性化药物治疗,并突出了计算建模在药物开发中的价值.
相关概念视频
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
268
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
268
Pharmacokinetic–Pharmacodynamic Relationship: Problems
129
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
129
Pharmacodynamic Models: Overview
161
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
161
Pharmacodynamic Models: Emax Drug–Concentration Effect Model
245
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
245
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
157
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
157
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97


